References: Choice of long-acting injectable antipsychotic for recovery and relapse prevention in adults and young people

  • Corbeil O, Essiambre AM, Bechard L, Roy AA, Huot-Lavoie M, Brodeur S, et al. Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation. Ther Adv Psychopharmacol 2022;12:20451253221136021. https://www.ncbi.nlm.nih.gov/pubmed/36405400
  • Early Psychosis Guidelines Writing Group, EPPIC National Support Program. Australian clinical guidelines for early psychosis. 2nd update ed. Melbourne: Orygen, the National Centre of Excellence in Youth Mental Health; 2016. https://www.orygen.org.au/Training/Resources/Psychosis/Clinical-practice-points/Australian-Clinical-Guidelines-for-Early-Psychosis
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2013;18(1):53–66. https://pubmed.ncbi.nlm.nih.gov/22124274/
  • Taipale H, Mehtala J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull 2018;44(6):1381–7. https://www.ncbi.nlm.nih.gov/pubmed/29272458
  • Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 2017;74(7):686–93. https://www.ncbi.nlm.nih.gov/pubmed/28593216